Get started
Rockwell Medical, Inc.Rockwell Medical, Inc.Rockwell Medical, Inc.

Rockwell Medical, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

RMTI trade ideas

RMTI Turned the Corner RMTI has everything you want in a questionable stock market. A Chart patter then bottomed with classic Head and Shoulder pattern and a break out. the company has multiple years delivering what they promised and forecast. And they are in a industry not controlled by the economy; a manufacturer of hemodialysis concentrates for kidney failure patients. Rockwell makes a compelling case that their company is now an indispensable, and growing, piece of that healthcare infrastructure.
NASDAQ:RMTILong
by jdouglas020
Rockwell Medical RMTIThis is a turn around story. New management changed the direction of how they did things and 2nd quarter earnings just released was recognition that they are on the right path. The chart tells the whole story and head and shoulder bottom and break out. Rockwell is a microcap manufacturer of hemodialysis concentrates for kidney failure patients, trading at under 1x full-year 2023 revenue. A company where there is no reason demand will not continue regardless of the economy. Several wall street analysis predict this is $9 dollar stock. But it is hard to argue that this stock will double in price from this point.
NASDAQ:RMTILong
by jdouglas020
Rockwell MedicaL - RMTIRockwell Medical RMTI has just completed a bottom bowl that started 11 months ago. The first Qtr. 2024 was the first profit improvement and the chart display strength with that Quarterly report. The MACD bottomed in August 2023 and has risen and continues to send strength sikgnals. The new management has improved sales and forecasted sales of $90+ M for the 2024 which would be a 12% improvements. The healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024. The chart action indicates that this second quarter report will exceed expectations and street estimates believe the stock could gain substantially over the near term. I forecast the stock price will double in 2024 to $4 per share.
NASDAQ:RMTILong
by jdouglas020
Buy $RMTIBuy: $1.0 to $1.10 Target-1 - $1.60 Target-2 - $2.20 Target-3 - $3.50 SL: $0.83 ROXADUSTAT PRESENTS A NEW OPPORTUNITY FOR TRIFERIC New anemia drug expected to transform treatment & change iron requirements for dialysis patients Roxadustat is a new approach to treatment of the anemia of CKD •A physiologic approach to anemia mgmt. with improved safety vs. ESA’s* • Expected approval in Q1 2021 Roxadustat patients will require less iron •Reduces hepcidin & increases iron binding capacity (circulating transferrin), improving bioavailability of body iron stores & reducing requirement for IV iron supplementation • Evidence presented at ASN 2020 shows a monthly iron requirement of ~52mg Triferic may be uniquely suited to meet iron requirements of HIF-PHI patients •Triferic provides 100% bioavailable iron, bypassing hepcidin block and donating directly to transferrin •Triferic in the dialysate alone (84mg per month) may be sufficient to meet iron needs of most roxadustat treated patients eli min ating the need for I.V. iron supplementation Rockwell planning on conducting Triferic Phase 4 study for adjunctive use with roxadustat •To be initiated after FDA approval of roxadustat TRIFERIC : INTERNATIONAL MARKET China •Partnered to commercialize Triferic with Wanbang Biopharmaceutical •Registrational study started treating patients in Jan’21 •Low to mid 20% royalty due to Rockwell on Net Sales; $35 million potential milestone payments India •Signed licensing agreement with Sun Pharma in January 2020 • NDA submitted LATAM •Distribution agreements in place and commercial launch in Peru and Chile expected Q1 2022 Canada •Distribution agreement in place; NDS submitted in May 2020 and accepted for filing in June 2020 S.Korea •Signed licensing agreement with Jeil Pharma in September 2020 •Jeil Pharma submitted NDAs for both Triferic and Triferic AVNU in January 2021. Europe / Japan •Discussions ongoing with potential partners for Triferic AVNU Do you DD, This is not investment advice
NASDAQ:RMTILong
by RNB98
RMTI best Penny stocks for Maech With our great trading  RMTI I will be having their FDA approval decision on March 28th but why do we care well already I had a previous history of those spikability but it's also running up in price . we have both positive and positive directional and some high-volume leading up to this approval that so I'm going to be violently starting this opportunity for some solid Prentice between running up member we tried before the reaction or after the reaction so that means that half of the battle is really before the reaction . It's run up offered both clean and consistent green days you can literally just buy in  validation this is great because it makes for a more passive position and means you're less likely to get in really quick job that is hard to catch a lot about . the analyst put it around 19$  which gives us a whopping 178% 
NASDAQ:RMTIShort
by UnknownUnicorn6877177
2